Hepatocellular carcinoma associated with tight‐junction protein 2 deficiency
Authors: Shengmei Zhou, Paula M. Hertel, Milton J. Finegold, Larry Wang, Nanda Kerkar, Jing Wang, Lee‐Jun C. Wong, Sharon E. Plon, Melissa Sambrotta, Pierre Foskett, Zhiyv Niu, Richard J. Thompson, A.S. Knisely
Journal: Hepatology (2015)

Potential conflict of interest: Dr. Thompson is employed by, owns stock in, is on the speakers' bureau of, and received grants from Shire. This work was partially supported by a grant to S.E.P. (NHGRI/NCI U01HG006485). Mutations in TJP2 (also named ZO‐2), encoding tight‐junction protein 2 (TJP2), cause an autosomal‐recessive form of progressive intrahepatic cholestasis.1 Association of TJP2 deficiency with hepatocellular carcinoma (HCC) in childhood has not been recognized. Case Reports Patient 1 A 26‐month‐old Caucasian female with intermittent jaundice of neonatal onset and unknown etiology, with normal‐range serum gamma‐glutamyltransferase (GGT) activity, presented with liver failure. Computed tomography revealed innumerable well‐defined hepatic masses. Serum alpha‐fetoprotein (AFP) level was high (171,000 ng/mL). Liver biopsy (Fig. 1A‐E) found moderately differentiated HCC (expressing glypican‐3, p53, and AFP) in a background of chronic cholestatic hepatitis with cirrhosis. Mutational analysis detected no significant variants in ABCB11. Both bile salt export pump (BSEP) and multidrug resistance protein 3 (Fig. 1F,G) were well expressed. Because these features may result from TJP2 deficiency, TJP2 was sequenced.1 Compound heterozygous mutations were found, with c.2668‐1G>T /c.2438dupT (p.Asn814Glnfs) (NM_004817.3). TJP2 expression was not immunohistochemically demonstrable, and claudin‐1 expression was markedly decreased (Fig. 1H,I), supporting the diagnosis of TJP2 deficiency. The patient died 3 weeks after admission. Autopsy confirmed multifocal HCC (0.5‐4.0 cm in the greatest dimension).Figure 1: Patient 1. Non‐neoplastic liver shows micronodular cirrhosis (A) and prominent rosetting with bile plugs in canalicular lumina (B). (C and D) Low‐ and high‐magnification views of HCC. Tumor cells show variable cytoplasmic clearing and round to oval, sometimes pleomorphic nuclei with variably sized nucleoli. Some cells contain distinct round to oval eosinophilic cytoplasmic proteinaceous inclusions (arrow in D). Macrosteatosis and mitosis (arrow in E) are also present. BSEP (F) and multiple drug resistance protein 3 (G) are well expressed in non‐neoplastic liver. (H) Complete absence of TJP2 staining in bile ducts. (I) Markedly decreased claudin‐1 staining in both cholangiocytes and canalicular margins. Control liver shows normal TJP2 expression in bile duct (inset in H) and strong claudin‐1 expression in both bile ducts and canaliculi (inset in I). (A) Trichrome stain. (B‐F) Hematoxylin‐eosin stain. Original magnification: ×40 for (A); ×100 for (C); ×200 for (B), (D), and (E); and ×400 for (F)‐(I).Patient 2 A 6‐month‐old Caucasian male was referred for persistent cholestasis with near‐normal GGT after hepatoportoenterostomy for presumed biliary atresia. His parents denied consanguinity. No etiology was defined; workup included Sanger sequencing of ABCB11. Liver biopsy found cholestatic hepatitis (Fig. 2A). Icterus resolved by age 19 months, but a growing lesion in the right liver lobe, with rising serum AFP, prompted liver transplantation (LT) at age 2 years. The explanted liver was cirrhotic, with multiple cholestatic nodules and a single, well‐encapsulated 2‐cm tumor that diffusely expressed AFP and glypican‐3; a central region of well‐differentiated HCC was found (Fig. 2B‐D). Blood and tumor whole‐exome sequencing found homozygosity for c.817delG (p.A273fs) in TJP2, predicted to cause a frameshift in all transcripts of TJP2. Sanger sequencing validated the mutation, for which each parent was heterozygous. TJP2 expression was absent (Fig. 2E), and claudin‐1 expression was markedly decreased in nontumoral liver. The patient is well 2 years post‐transplantation.Figure 2: Patient 2. (A) Liver biopsy at 6 months displays severe cholestasis, giant cell transformation, and micronodular cirrhosis. (B) Macroscopic photograph of the explant reveals multiple cholestatic nodules and one much larger and softer tan nodule with focal bile pigmentation (arrow), within which HCC was found histologically. (C) Within the large, soft nodule, a sharply delineated smaller aggregate of highly pleomorphic, mitotically active cells (arrows) is typical of HCC. (D) Glypican‐3 expression (brown staining) is observed in HCC and regenerative nodule, but not in non‐neoplastic hepatocytes (left upper). (E) TJP2 is not expressed at bile canaliculi of the patient's liver biopsy specimen, whereas it is observed anomalously in hepatocyte nuclei. Control liver shows normal canalicular expression of TJP2 (inset). (A and C) Hematoxylin‐eosin stain. Original magnification: ×125 for (D) and ×200 for (A), (C), and (E).Discussion Both patients had clinical and histological features similar to those of BSEP deficiency, which predisposes to HCC in childhood.2 However, neither ABCB11 mutation nor BSEP deficiency was demonstrable. Instead, biallelic TJP2 truncating mutations were found in both cases. TJP2 expression at cholangiocyte apices and bile canaliculus margins was entirely absent. As with Sambrotta et al.,1 we found deficiency of canalicular claudin‐1 expression. Therefore, we ascribe liver disease in both patients to severe TJP2 deficiency.​ We infer that TJP2 deficiency predisposes to HCC development in early childhood. How it does so is unclear. Though many toddlers have severe cholestatic liver disease, very few develop HCC. This makes an indirect and nonspecific effect of TJP2 deficiency unlikely. Down‐regulation of TJP2 function in various tumor types3 may suggest direct tumorigenesis. However, such down‐regulation is perhaps secondary and nonspecific. HCC in children with BSEP deficiency may arise by several routes. A case in which mutations such as those found in adult HCC underlay tumorigenesis is reported,4 as are several cases in which massive gene amplification was found.5 These mechanisms remain to be assessed in pediatric HCC with backgrounds of other cholestatic disorders, including TJP2 deficiency. TJP2 mutation must be considered in patients with intrahepatic cholestasis and normal‐range GGT. TJP2 deficiency may predispose to HCC in early childhood, warranting close monitoring and early LT.